Galecto develops small molecules for the treatment of severe diseases, including fibrosis, cancer, and inflammation – for more information see: Products.
Galecto was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark
The company builds on more than 12 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat liver fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets provide Galecto with a unique therapeutic platform.
Galecto’s lead product candidate, GB1211, an orally delivered galectin-3 inhibitor, is in development for the treatment of decompensated cirrhosis, a very serious liver condition with high mortality. The company’s pipeline also includes GB2064, an inhibitor of lysyl oxidase like 2, or LOXL2, an enzyme directly involved in the formation of fibrosis which we initially plan to develop in myelofibrosis.